Recruiting

Integrated Cancer Repository for Cancer Research

ClinicalTrials.gov IDNCT02012699

PhaseNot Applicable

Enrollment999999

SponsorUniversity of Nebraska

Age19 Years

SexALL

I'm interested View official listing

Conditions studied

Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control

About this study

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Primary outcomes

Development and Implementation of a Web-based Cancer Collaborative Registry (86 years)

Eligibility information

Inclusion Criteria * Diagnosis/history of cancer * Risk for developing cancer or suspicious clinical findings * No history of cancer (normal control registry) * Able to provide informed consent * 19 years of age or older * English or Spanish speaking individuals Exclusion Criteria * Unable to provide informed consent because of cognitive impairment * Non-English or non-Spanish speaking individuals

Study locations

Advent Health, Greenwood Village, Colorado 80111 United States
Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester, Connecticut 06040 United States
Florida Hospital Memorial Medical Center, Daytona Beach, Florida 32117 United States
Florida Hospital DeLand, DeLand, Florida 32720 United States
Florida Hospital FISH, Orange City, Florida 32763 United States
Florida Hospital Flagler, Palm Coast, Florida 32164 United States
Tallahassee Memorial Hospital, Tallahassee, Florida 32308 United States
Rush-Copley Cancer Care Center, Aurora, Illinois 60504 United States
Rush-Copley Healthcare Center, Yorkville, Illinois 60560 United States
Parkview Research Center, Fort Wayne, Indiana 46845 United States

Showing 10 of 42 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.